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Abstract
Background: Muscle strength declines on average by one percent annually from midlife on. In postmenopausal women this
decrement coincides with a rapid decline in estrogen production. The genetics underlying the effects of estrogen on
skeletal muscle remains unclear. In the present study, we examined whether polymorphisms within COMT and ESR1 are
associated with muscle properties and assessed their interaction and their combined effects with physical activity.
Methodology/Principal Findings: A cross-sectional data analysis was conducted with 434 63-76-year-old women from the
population-based Finnish Twin Study on Aging. Body anthropometry, muscle cross-sectional area (mCSA), isometric hand
grip and knee extension strengths, and leg extension power were measured. COMT Val158Met and ESR1 PvuII genotypes
were determined by the RFLP method. mCSA differed by COMT genotypes (p = 0.014) being significantly larger in LL than
HL individuals in unadjusted (p = 0.001) and age- and height-adjusted model (p = 0.004). When physical activity and age
were entered into GEE model, COMT genotype had a significant main effect (p = 0.038) on mCSA. Furthermore, sedentary
individuals with the HH genotype had lower muscle mass, strength and power, but they also appeared to benefit the most
from physical activity. No association of ESR1 PvuII polymorphism with any of the muscle outcomes was observed.
Conclusions/Significance: The present study suggests that the COMT polymorphism, affecting the activity of the enzyme, is
associated with muscle mass. Furthermore, sedentary individuals with potential high enzyme activity were the weakest
group, but they may potentially benefit the most from physical activity. This observation elucidates the importance of both
environmental and genetic factors in muscle properties.
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Introduction
One of the most important functions of skeletal muscle is
voluntary movement. Muscle also serves as an amino acid
reservoir and a site for various metabolic activities participating
e.g. to the glucose metabolism of the whole body [1,2]. Absolute
muscle mass is again critical, when the body has to recover from
critical illnesses or traumatic injuries [3]. From midlife on, muscle
strength declines, approximately one percent annually [4]. This
decline may eventually predispose people to mobility limitation,
falls and bone fractures [5–7]. Individual differences in muscle
phenotypes in old age may be explained by both environmental
and genetic factors [8–12].
In women, menopause is characterized by rapid decline in the
production of estrogen, an anabolic female sex hormone, and
coincides with an accelerated deterioration in muscle performance
[13,14]. At phenotype level hormone replacement therapy (HRT)
exerts positive effects on skeletal muscle in some of the
randomized, controlled trials reported [15–18], whereas others
have documented contradictory results [19–21]. Moreover, a
combination of high-impact training and HRT usage has been
reported to exceed the beneficial effects of HRT alone [15].
Furthermore, in animal studies estrogen has been shown to
contribute to skeletal muscle growth via specific receptors [22,23].
Given this putative role of estrogen in muscle function, genes
related to estrogen action and metabolism are likely candidates
contributing to the genetic component of muscle properties.
The synthesis and degradation of estrogens are mediated by
several enzymes involved in multiple and complex metabolic
pathways. After initial hydroxylation of estrogens by isoenzymes
belonging to the cytochrome P450 family, they are further
metabolized by catechol-O-methyltransferase (COMT) into more
inactive methoxyestrogens. These O-methylated metabolites no
longer bind to estrogen receptors (ESRs) [24], which mediate the
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effects of estrogen in target tissues [25]. A functional G to A
polymorphism in the fourth exon of COMT gene results in a valine
to methionine amino acid transition at codon 158 (COMT
Val158Met polymorphism) leading to thermolability [26,27] and
lower activity of the enzyme. This could hence increase the
availability of estrogen and induce the anabolic effects of this
hormone on target tissues such as skeletal muscle. COMT
represents an intracellular enzyme present in a variety of tissues
[28]. Previous studies with men [29,30], early pubertal girls [31],
as well as premenopausal [32] or postmenopausal women [33–35]
have reported contradictory results, whether this polymorphism is
actually associated with estrogen levels or not. To our knowledge,
no studies have been published, in which the relationship of this
polymorphism with skeletal muscle characteristics has been
investigated.
ESR1 was recently shown to be expressed in human skeletal
muscle [36] implying that skeletal muscle is sensitive to estrogen
signaling, albeit to date the overall effects of estrogen on skeletal
muscle remain poorly understood. PvuII polymorphism in the first
intron of ESR1 gene (ESR1 PvuII polymorphism) identifies a
nucleotide T to C transition resulting in the loss of PvuII
restriction site [37], which has been suggested to affect the
magnitude of ESR1 transcription or production of various
ESR1 isoforms [38]. More precisely, the C variant, also denoted
as the P allele, is suggested to lead to the amplification of
ESR1 transcription. In previous reports, no association of this
polymorphic site with isometric muscle strength has been found
[39,40].
Theoretically, polymorphisms residing in genes related to
estradiol metabolism and action, in this case COMT and ESR1,
may have shared effects on estradiol signaling in target tissues.
More precisely, a polymorphism affecting the activity of COMT
may directly or indirectly modulate the amount of estradiol
available to be bound by membrane-bound or intracellular
estrogen receptors, whereas a polymorphism potentially modulat-
ing the amount of ESR1 transcript may further affect the
availability of these receptors. On the other hand, the two
estrogen-related polymorphisms under investigation may act in
conjunction with physical activity resulting in a specific muscle
phenotype. Our aim was to determine whether the two estrogenic
polymorphisms, COMT Val158Met and ESR1 PvuII, are
associated with serum estradiol levels and skeletal muscle
phenotypes or not. Furthermore, we studied the interaction of
these polymorphisms and their interaction with physical activity.
Methods
Study subjects
This study is a part of the Finnish Twin Study on Aging
(FITSA), which investigates the genetic and environmental effects
on the disablement process in older female twins. The detailed
study design, including selection procedures, determination of
zygosity and description of the participants, has been reported
elsewhere [10]. Briefly, participants were recruited from the
Finnish Twin Cohort [41,42] consisting of 13 888 twin pairs. 103
monozygotic and 114 dizygotic female twin pairs (total n = 434
subjects) aged 63–76 years (mean 68.6 years, SE 0.16) were
invited to laboratory investigations performed in Jyva¨skyla¨ during
2000–2001. Shared willingness to participate obtained from both
sisters was a prerequisite for recruiting. Zygosity was determined
with a battery of ten highly polymorphic gene markers using DNA
extracted from a venous blood sample. The Ethics Committee of
the Central Finland Hospital approved the study and it was
conducted according to the guidelines in The Declaration of
Helsinki. The subjects signed an informed consent before
participating in the measurements.
In the whole study sample the prevalence of various diseases
potentially effecting muscle properties were: 12 % for coronary
heart disease, 8 % for asthma, 7 % for cerebrovascular disease, 6
% for type 2 diabetes, 4 % for rheumatoid arthritis, 29 % for knee,
14 % for hip and 12 % for foot and ankle osteoarthritis. 67 % of all
the subjects had never used HRT, whereas 14 % were former
users and 19 % current users. Moreover, 3 % of the subjects in the
entire population were current cortisol users and 12 % former
users, whereas 85 % had never been under long-term cortisol
treatment. Subjects with the above-mentioned diseases and
different HRT or cortisol status were equally distributed between
genotypes.
Phenotyping
Hormone measurements. Nonfasting blood samples were
collected between 0830 and 0930 hours and sera stored at 270uC
for later analysis. Total serum 17b-estradiol was determined by
competitive immunoenzymatic colorimetric assay (NovaTec
Immunodiagnostica GmbH, Dietzenbach, Germany) and serum
sex hormone binding globulin (SHBG) levels using solid-phase,
chemiluminescent immunometric assay (ImmuliteH 1000 SHBG,
DPC [Diagnostic Products Corporation], Los Angeles, USA). Free
estradiol levels were calculated from 17b-estradiol and SHBG
levels according to a previously presented method [43,44]. In our
laboratory, intra- and interassay coefficient of variations (CVs)
were 3.2 % and 3.2 % for 17b-estradiol and 2.3 % and 6.5 % for
SHBG, respectively.
Body anthropometry. Body mass and body height were
measured using standard procedures. Lean body mass and total
body fat were assessed by bioelectrical impedance (Spectrum II;
RJL Systems, Detroit, MI, USA). The CV in our laboratory has
been less than 2 % for lean body mass and less than 3 % for body
fat [45]. Lower leg muscle cross-sectional area (mCSA), which
gives an estimate of muscle mass, from the dominant hand side
was assessed by peripheral quantitative computed tomography
(pQCT, XCT-2000, Stratec Medizintechnik, Pforzheim,
Germany). Tomography slices of two millimeters were obtained
at 55 % upwards from the joint surface of the distal tibia. The
whole mCSA of lower leg, i.e. the tissue area excluding
subcutaneous fat and bones, was determined by Bonalyse 1.3
(Commit; Ltd, Espoo, Finland). CV for mCSA in our laboratory
was 1 %.
Muscle strength and power. Maximal isometric strength,
defined as the maximum voluntary contraction performed at a
specific joint ankle against unyielding resistance, was measured for
knee extension and hand grip. Maximal isometric hand grip and
knee extension strengths were measured on the dominant side in a
sitting position using an adjustable dynamometer chair (Good
Strength, Metitur, Jyva¨skyla¨, Finland). After familiarization with
the test, three to five maximal efforts separated by a one-minute
interval were conducted. Mid-life maximal isometric hand grip
strength, strength of a non-bearing limb, has been reported to
correlate with strength of other muscle groups thus being a good
indicator of overall strength [46], and also to be highly predictive
of mortality and functional disability in later life [47,48]. Knee
extension strength, on the other hand, represents the strength of a
bearing limb, potentially prone to physical exercise or disuse.
Knee extension strength is important for functional capacity as
decline in strength together with poor balance is reported to
predict severe walking disability [49]. Leg extensor power of single
leg was assessed according to published guidelines [50] using the
Leg Extensor Power Rig (Nottingham, UK). Leg extension power
COMT, ESR1 and Skeletal Muscle
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measures the ability of the neuromuscular system to produce the
greatest possible force as fast as possible. After two to three
practice trials, five to nine maximal efforts were conducted. In all
measurements, the best performance with the highest value was
accepted as the result for each subject. CVs between two
consecutive measurements have in our laboratory been 6 % for
knee extension and hand grip strengths [51] and was 8 % for leg
extension power in the present study. Physician evaluated possible
contraindications for muscle strength and power measurements.
All the subjects were able to perform at least one of the above-
mentioned measurements.
Physical activity. Information concerning physical activity
was collected using the scale of Grimby [52] with slight
modifications. The participants were categorized on the basis of
their self-reported physical activity as sedentary group (no other
activities, but at the most light walking #2 times/week),
moderately active (walking or other light exercise at least 3
times/week, but no other more intensive activities) and active
(moderate or vigorous exercise at least 3 times/week). Of the entire
population, 32 % were sedentary (sed), 48 % moderately active
(mod) and 20 % active (act) according to this division. Subjects
with various physical activity levels were equally distributed within
the genotypes.
Genotyping
Genomic DNA was extracted from EDTA-anticoagulated
whole blood according to standard procedures (PUREGENEH
Kit, Gentra Systems Inc., Minneapolis, USA). Genotyping for
Val158Met and PvuII polymorphisms was performed using PCR
(thermal cycler: EppendorfH MastercyclerH gradient, Eppendorf,
Boulder, CO, USA) followed by restriction fragment length
polymorphism (RFLP) analysis [37,53].
COMT Val158Met. The G to A transition at the 158th codon
in the COMT gene was determined by copying a 109-bp fragment
with a primer pair (Oligomer Oy, Helsinki, Finland) including
forward (59-CTCATC ACCATC GAGATC AA) and reverse
primers (59-CCAGGT CTGACA ACGGGT CA) [54]. PCR
reaction mixture of 15 ml contained 35 ng of DNA, 0.13 mM of
both primers, 0.4 mM of dNTP mix (Eppendorf, Boulder, CO,
USA) and 1,5 U of HotMaster Taq polymerase (Eppendorf,
Boulder, CO, USA). PCR conditions included a pre-incubation
period of 2 min at 95uC after which the DNA was subjected to 40
cycles of 95uC for 1 min, 54uC for 1 min and 72uC for 1 min
followed by final extension step of 5 min at 72uC. The resulting
PCR product was digested by adding 5 U of NlaIII restriction
endonuclease (New England Biolabs, Ipswich, MA, USA) and
incubated overnight at 37uC. The resulting fragments were
separated in a 4.5 % agarose gel and the genotypes determined.
Genotypes were coded as HH, HL and LL, in which capital H
denotes the presence of valine and thus high activity allele,
whereas L refers to the presence of methionine and the low activity
allele.
ESR1 PvuII. In ESR1 PvuII genotyping a 373-bp PCR
fragment was produced using a primer pair (Oligomer Oy, Helsinki,
Finland) consisting of forward (59-GATATC CAGGGT TATGTG
GCA) and reverse primers (59-TTACCT CTTGCC GTCTGT
TGC) in a 10 ml reaction mixture containing 20 ng of DNA,
0.1 mM of both primers, 0.4 mM of dNTP mix (Eppendorf,
Boulder, CO, USA) and 0.35 U of HotMaster Taq polymerase
(Eppendorf, Boulder, CO, USA). PCR reaction was carried out
with the following steps: preheating at 95uC for 2 min followed by
36 cycles, in which denaturation was performed at 94uC for 45 s,
annealing for 45 s with gradually declining temperature (36 cycles
with declining temperature from 67uC to 60uC) and extension at
72uC for 45 s. The PCR product was digested by adding 5 U of
PvuII restriction endonuclease (InvitrogenTM, Carlsbad, CA, USA)
and incubated for two hours at 37uC. The digested products were
further separated by electrophoresis in a 3 % agarose gel. Genotypes
were determined due to resulting fragments and coded as PP, Pp
and pp. Uppercase letters indicate the absence and lowercase letters
the presence of a restriction site.
RFLP identification was carried out by two independent
investigators from whom data on phenotypes was concealed.
Genotyping was successfully performed in 423 for COMT
Val158Met and 421 for ESR1 PvuII site out of 434 subjects.
Reasons for missing determinations include insufficient amount of
DNA or contamination of the blood sample.
Statistical analyses
Hardy-Weinberg equilibrium was tested using the likelihood
ratio test. Allele frequencies were determined by gene counting.
All statistical models were constructed in SAS, version 9.1 using
the generalized estimating equations approach (GEE), which
allows taking into account the correlation between sisters within a
twin pair. All outcome variables were normally distributed except
for estradiol concentrations, which were skewed towards low
concentrations and were considered to follow the gamma-
distribution. Two types of single genotype models were construct-
ed, one including the unadjusted main effects of the genotypes,
and the other adjusted for age and height. To assess genotype-
genotype and genotype-physical activity interactions a reference
category was selected for the categorical predictor variables of
physical activity (sedentary level), COMT (the HH genotype) and
ESR1 Pvull (the pp genotype). Planned contrasts were used in
comparing mean levels of each outcome variable between the
predictor variable levels and their interactions against the
reference category. Test-wise type I error rate was set at 0.05 in
all analyses and partial correlation coefficients from the GEE
model contrasts [55] were computed as estimates of effect size.
We hypothesized that subjects with assumed lower amount of
circulating estradiol (HH genotype) and potential lower levels of
ESR1 transcript (pp genotype) would be less responsive to estradiol
and thus have worse muscle properties in comparison with other
combinations. In the models including physical activity, subjects
with potential low amount of circulating estradiol (HH genotype)
or suggested low amount of ESR1 transcript (pp genotype)
combined with sedentary life-style, were assumed to be weaker and
have smaller muscles than other combinations. In our approach,
reference groups were chosen according to these initial hypothesis
and the mean values of other groups compared to that of the
reference groups. The reference groups for the interaction effect
were formed based on the combination of the main effect
reference categories. The main effects of the two components of
interest are always presented in contrast to the reference group.
Results
COMT Val158Met genotype
In our study population 79 subjects (18.0 %) were homozygous
for the high activity allele (HH), 208 (47.9 %) heterozygotes (HL)
and 137 (31.6 %) homozygous for the low active allele (LL). The
allele frequencies were 0.43 for the H and 0.57 for the L allele.
The genotype distribution of the entire cohort was in Hardy-
Weinberg equilibrium (x2 = 0.004, p= 0.95) suggesting that the
subjects represented a homogeneous genetic background. Subject
characteristics according to Val158Met genotypes are presented in
Table 1. Physical characteristics and estradiol levels were similar in
all Val158Met genotypes. However, mCSA was significantly larger
COMT, ESR1 and Skeletal Muscle
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in LL than HL individuals both in the unadjusted model
(p = 0.001, data not shown) and after adjusting with age and
height (p = 0.004, Table 1). No statistically significant association
between Val158Met genotype and hand grip strength, knee
extension strength or leg extension power was found.
ESR1 PvuII genotype
The most common genotype was Pp (n= 187, 43.1 %), whereas
pp genotype was more frequent (n = 144, 33.2 %) than PP (n= 90,
20.7 %). The allele frequencies were 0.44 and 0.56 for the P and p
alleles, respectively. The genotypes were slightly out of Hardy-
Weinberg equilibrium (x2 = 3.943, p = 0.047) suggesting that our
study sample may not be representative of the target population.
Physical characteristics, including hormone levels, were similar in
all PvuII genotypes. Furthermore, PvuII polymorphism was not
associated with any of the measured muscle variables (Table 2).
Interaction of COMT and ESR1 polymorphisms with
respect to muscle properties
We further studied whether ESR1 modified the effects of
COMT. The results of age-adjusted models are shown in Table 3.
In the model including COMT and ESR1 genotypes COMT-
Val158Met polymorphic site had a main effect on mCSA. More
precisely, individuals with the HH genotype had significantly
smaller muscle mass than LL subjects (p = 0.038). Furthermore, a
significant interaction was present in knee extension strength
between HH and LL subjects (p = 0.031). Here, the mean
difference between the comparison and reference groups was
Table 1. Body composition, hormone levels and muscle properties categorized according to COMT Val158Met genotypes.
Variable COMT genotypes p for trend
HH (n=79) HL (n=208) LL (n=136–137)
Weight (kg) 70.0 (1.7) 70.3 (1.0) 70.0 (1.2) 0.972
Height (cm) 157.5 (0.87) 158.2 (0.53) 159.7 (0.66) 0.085
Body fat (kg) 24.0 (1.1) 24.5 (0.8) 23.6 (0.87) 0.763
Lean body mass (kg) 46.1 (0.68) 45.6 (0.36) 46.5 (0.47) 0.194
BMI (kg/m2) 28.2 (0.7) 28.2 (0.4) 27.6 (0.5) 0.565
Estradiol (nmol/l) 0.29 (0.051) 0.35 (0.054) 0.39 (0.069) 0.462
Free estradiol (nmol/l) 0.0059 (0.0008) 0.0073 (0.0010) 0.0083 (0.0015) 0.242
(n = 74–79) (n =193–208) (n=131–136)
Muscle CSA (mm2)* 5950.9 (109.8) 5880.6 (73.7) 6199.8 (91.5) 0.0141
Hand grip strength (N)* 190.6 (6.0) 189.3 (3.8) 194.0 (5.7) 0.763
Knee extension strength (N)* 352.5 (17.2) 322.5 (14.7) 343.4 (16.7) 0.092
Leg extension power (W)* 101.0 (4.2) 99.1 (2.6) 100.9 (3.4) 0.858
Data are mean (SE).
*Adjusted for age and height
1Contrasts: COMTLL vs. COMTHL (p = 0.004); COMTLL vs. COMTHH (p = 0.078); COMTHL vs. COMTHH (p = 0.569)
doi:10.1371/journal.pone.0001819.t001
Table 2. Body composition, hormone levels and muscle properties categorized according to ESR1 PvuII genotypes.
Variable ESR1 genotypes p for trend
PP (n =90) Pp (n =187) pp (n =144)
Weight (kg) 70.3 (1.4) 69.6 (1.1) 70.7 (1.3) 0.797
Height (cm) 159.2 (0.88) 158.3 (0.58) 158.5 (0.63) 0.669
Body fat (kg) 24.3 (1.1) 23.7 (0.7) 24.6 (1.0) 0.664
Lean body mass (kg) 46.3 (0.52) 45.7 (0.44) 46.2 (0.44) 0.573
BMI (kg/m2) 27.8 (0.6) 27.9 (0.4) 28.3 (0.5) 0.813
Estradiol (nmol/l) 0.36 (0.08) 0.31 (0.04) 0.40 (0.08) 0.584
Free estradiol (nmol/l) 0.0075 (0.0017) 0.0062 (0.0006) 0.0086 (0.0017) 0.375
(n = 81–90) (n=177–187) (n =136–144)
Muscle CSA (mm2)* 6124.6 (121.5) 5927.3 (81.8) 6002.5 (97.4) 0.393
Hand grip strength (N)* 192.0 (6.3) 190.3 (4.4) 192.3 (5.2) 0.950
Knee extension strength (N)* 347.7 (17.8) 337.2 (14.8) 323.2 (15.1) 0.416
Leg extension power (W)* 99.2 (3.5) 98.3 (2.5) 103.5 (3.7) 0.494
Data are mean (SE).
*Adjusted for age and height
doi:10.1371/journal.pone.0001819.t002
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261.44, suggesting that an addition of two P alleles to LLpp
genotype (LLppRLLPP) leads to a lesser increase in knee
extension strength in comparison to the HH genotype
(HHppRHHPP). Other interaction effects between COMT
Val158Met and ESR1PvuII polymorphisms were not significant.
Interaction of COMT or ESR1 polymorphism and physical
activity with respect to muscle properties
In further analyses we examined whether physical activity level
modulates the effects of COMTVal158Met (Table 4 and Figure 1)
or ESR1PvuII (Table 5) polymorphism on muscle properties. In
the model including the COMT genotype, physical activity and
age as explanatory variables, the genotype had a statistically
significant main effect on mCSA; LL subjects were greater than
HH subjects in their muscle size (p = 0.021). As expected, physical
activity had a significant main effect on all the muscle strength and
power variables (sedentary subjects were weaker than moderately
active or active individuals, p#0.004 for all comparisons), but the
effect on mCSA was less clear (p$0.078 for all comparisons).
Significant interaction effects of the COMT genotype and physical
activity were present in all muscle variables. In knee extension
strength and leg extension power, all the interaction effects were
statistically significant (p,0.05 for all comparisons). The mean
differences imply that in all these comparisons, an increase in
physical activity from sedentary to moderate or from sedentary to
active level within the HH genotype, creates a larger increase in
both knee extension strength and leg extension power than among
HL or LL individuals (p#0.045). This trend was also evident in
mCSA, although the effect between HH and HL subjects was not
statistically significant when sedentary and active individuals were
compared (p= 0.41). In hand grip strength a significant interaction
effect was observed only between HH and HL individuals, when
sedentary subjects were compared to their moderate active
counterparts (Mdf =236.76, p= 0.011). In general, the mean
values of sedentary HH subjects in all the measured muscle
outcomes were lower than subjects with other genotype and/or
physical activity level (Figure 1). Moderately active or active
subjects with HH genotype, however, had comparable values to
those of other genotypes. The partial correlations for the main and
interaction effects indicate that the effect sizes were small (0.1) or
moderate (0.3) in all significant effects.
In the model including ESR1 genotype, physical activity and
age as explanatory variables, physical activity had a main effect on
muscle strength and power (sedentary subjects were weaker than
moderately active or active individuals, p#0.004, Table 5), but
this effects was not observed in mCSA. Neither main effects of
ESR1 nor interaction effects of ESR1 genotype and physical
activity on any of the studied muscle properties were present.
Discussion
In the present study we examined the contribution of inter-
individual variation in two candidate genes involved in estrogen
metabolism and action, COMT and ESR1, to skeletal muscle
properties in older women. We hypothesized that variation in
these genes, essentially Val158Met polymorphism within COMT
and PvuII polymorphism within ESR1, alone or together with
physical activity may, at least partly, modulate muscle mass and
performance phenotypes in older women. Our results suggest that
COMT Val158Met polymorphism is associated with muscle mass
in that subjects with the LL genotype have significantly larger
muscles than heterozygotes. Furthermore, within the subjects with
HH genotype – leading to the presumed higher COMT activity –
and sedentary life-style, lower levels of muscle mass, strength and
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power were observed than within other sedentary subjects or
subjects with more active life-style.
Since the O-methylation of catechol estrogens by COMT occurs
rapidly [24], Val158Met polymorphism within COMT may have
significant contribution to circulating estrogen levels by mediating
the activity of the enzyme. In the present study no statistically
significant differences in total or free estradiol levels between
different COMT genotypes were found, but there was a gradient,
albeit not statistically significant, towards lower estradiol levels in
HH individuals. Our subjects were postmenopausal women
characterized by relatively low serum estradiol levels making their
measurement with a direct assay difficult [56], thereby possibly
affecting the accuracy of the results. From our data, the possibility
that during the pre-menopausal years of our study subjects, i.e. the
majority of their life-span, their estradiol levels may have been
affected by COMT genotype, cannot be excluded. If so, their
present muscle properties would also have been vulnerable to the
effects of different hormone levels during these pre-menopausal
years. Here, we can not rule out this period of their life, which
certainly is evident in their present muscle phenotype. Thus far,
contradictory results exist, whether this genotype can really affect
free estradiol levels or not. In pubertal girls Val158Met genotype
has been reported to affect free estradiol levels in that subjects with
the low activity variant have higher levels of circulating estradiol
[31]. Additionally, the same polymorphism has been demonstrated
to result in higher bone mineral density in young men carrying the
H allele compared to non-carriers [29] as well as increased non-
vertebral fracture risk in elderly men with the L allele [30] without,
however, an evident connection to free circulating estradiol levels.
However, in postmenopausal women receiving an oral estradiol
preparation, serum estradiol levels correlated significantly with
Val158Met genotype [35], whereas no direct association between
estradiol levels and Val158Met polymorphism was found else-
where [32–34].
Our results suggest that Val158Met polymorphism affects
muscle size such that LL genotype favors larger muscle cross-
sectional area. This result is supported by a similar outcome in a
study with early pubertal girls [31]. In previous studies muscle
mass has been reported to be under rather strong genetic control
[11,12], whereas genetic effects explained muscle strength and
power to a lesser extent [9,10].
In our study sample, no association between PvuII polymor-
phism in ESR1 and serum estradiol levels, or muscle structure or
function was found. This supports the results from previous
reports, in which no connection between this polymorphism and
hand grip [39,40] or quadriceps isometric strength [39] has been
found. The biological significance of PvuII polymorphism is
hitherto unclear. Loss of PvuII restriction site has been reported to
result in a potential binding site for B-myb transcription factor and
in some settings this further led to induced transcription of a
reporter gene [38]. In addition to this possibility to influence the
mRNA levels of ESR1, the connections of PvuII polymorphism to
e.g. bone phenotypes recognized so far may be due to some
unknown polymorphism residing in close proximity of and being
in linkage disequilibrium with PvuII locus within ESR1. This
polymorphic site within ESR1, or less likely within an adjacent
gene, may affect bone, but not muscle properties supporting our
results together with the findings from previous studies [39,40].
In theory, polymorphisms within COMT and ESR1 genes may
act in concert by regulating the availability of estrogen and
estrogen receptors, respectively. To the best of our knowledge, the
present study is the first to examine, whether the genetic variation
in ESR1 modulates the effects of COMT Val158Met on muscle
properties. According to our results, COMT genotype has a main
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effect on muscle CSA regardless of the ESR1 genotype. Moreover,
we observed an interaction effect of these polymorphisms on knee
extension strength. This effect, however, seemed sporadic, given
the small effect size and since other interaction effects were not
present. Further studies are warranted in order to confirm this
finding.
In the GEE model dissecting the interaction effects of COMT
Val158Met polymorphism and physical activity on muscle
properties a more clear gradient of the effects was observed. The
HH subjects showed more variation in relation to physically active
life-style compared to other genotypes as measured by knee
extension strength and leg extension power. For example, the
adjusted mean values in moderately active subjects with the HH
genotype were 36.7 % higher in knee extension strength than in
sedentary subjects with the same genotype, whereas within the HL
genotype this difference was only 7.9 % in the favor of the
moderately active subjects (Figure 1). In general, the sedentary
subjects with the HH genotype were the weakest group, but those
with the same genotype and more active life-style had comparable
muscle properties to that of other genotypes with whichever level
of activity. These data suggest that individuals with presumed low
levels of circulating estradiol and thereby its minor effect on
skeletal muscle can be prone to low muscle mass, strength and
power, which may, however, be compensated for by physically
active life-style. A clinical trial of muscle training among sedentary
subjects with differing genotypes would be needed to confirm these
observational data.
Physical activity had a significant main effect on muscle strength
and power measures, in the models investigating the interaction
effects between COMT or ESR1 genotype and physically active
life-style. Here, both moderately active and active individuals were
stronger than sedentary subjects. In muscle mass, however, the
effect was less clear or absent. This observation shows that our
assessment of physical activity level with the modified scale of
Grimby was in accordance with our expectations in muscle
performance variables, but not in muscle mass. This notion seems
reasonable taken into account the general mode of physical activity
in older subjects; physical activity in the ages around 60 and 70 in
general is not hypertrophying that would be evident as an increased
muscle mass, but rather includes various types of aerobic everyday
activities affecting the properties of muscle performance. Our
assessment was clearly able to differentiate sedentary individuals
from more active ones in the model investigating the interaction of
physical activity with the COMT genotype.
A limitation of the present study is the relatively small sample
size, which may have also been selected towards rather healthy
women creating a possible healthy population bias. Moreover, we
present results from various measurements describing muscle
strength. Our test battery includes variables presenting both
isometric (hand grip and knee extension strength) and dynamic
(leg extension power) muscle performance as well as measures
from both lower and upper limbs. Furthermore, during isometric
testing, the speed of muscle contraction is not as essential as in
muscle power measurements. On the other hand, these data
provide a multifaceted estimate of the effects of the chosen
genotypes on whole body musculature. The results provided by
our cross-sectional data set should be further confirmed in a
follow-up study and, if possible, with a larger sample and an
Figure 1. Muscle CSA, hand grip strength, knee extension strength and leg extension power according to COMT genotype and
physical activity. Diagram presents the mean values (+SE) for CSA, hand grip strength, knee extension strength and leg extension power from GEE
model according to COMT genotypes (HH, HL and LL) and physical activity (sed for sedentary, mod for moderately active and act for active). The
model is adjusted with age. Results from statistical testing are shown in Table 4.
doi:10.1371/journal.pone.0001819.g001
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intervention trial to see, if the response to training is actually
genotype-dependent.
In conclusion, the identification of the genetic susceptibility
factors predisposing the elderly to impaired muscle performance
could provide novel insights into the etiology of sarcopenia and
would enable the recognition of those people at high risk of
disability. Analysis of genetic variants, such as SNPs, represents a
powerful approach to examine the role of candidate genes in the
progression of this obviously multifactorial state. In the present
study, we found an association between a polymorphism in the
COMT gene and muscle mass. Furthermore, the interaction effect
of this polymorphism and physical activity on muscle mass,
strength and power elucidates the interplay of environmental and
genetic factors in muscle properties and represents an example of
how an unfavorable genetic background may perhaps be
compensated for by healthy living habits, in this case physical
activity. Overall, our results imply that COMT gene, related to the
metabolism of estrogens, may be connected with muscle
properties, albeit the exact mechanisms remain unknown.
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